Výsledky vyhledávání - "A Arzola-Paniagua"

Akademický článek

A randomized, clinical trial of ketorolac tromethamine vs ketorolac trometamine plus complex B vitamins for cesarean delivery analgesia

Autor: J J Beltrán-Montoya, T Herrerias-Canedo, A Arzola-Paniagua, F Vadillo-Ortega, Omar Felipe Dueñas-Garcia, H Rico-Olvera

Publikováno v: Saudi Journal of Anaesthesia, Vol 6, Iss 3, Pp 207-212 (2012)

Background: Ketorolac is widely used for postoperative analgesia in patients who undergo cesarean delivery. In countries where the use of opioids is considerably restricted, alternatives to narcotics are required. Aim: We hypothesize that the additio

Externí odkaz: https://doaj.org/article/c407ace03ea148768dd16b2432e46fd1

Zobrazit plný text záznamu

Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

Autor: Cesar G. Calvo-Vargas, Enrique Raúl García-Salgado López, Martha Guevara-Cruz, María Angélica Arzola-Paniagua

Publikováno v: Obesity. 24:1454-1463

Objective To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period. Methods This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dae2b1d723d7fdd21639cb7919a47126
https://doi.org/10.1002/oby.21523

Zobrazit plný text záznamu

Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

Autor: María Angélica, Arzola-Paniagua, Enrique Raúl, García-Salgado López, Cesar G, Calvo-Vargas, Martha, Guevara-Cruz

Publikováno v: Obesity (Silver Spring, Md.). 24(7)

To evaluate the efficacy of an orlistat-resveratrol (O-R) combination in subjects with obesity over a 6-month period.This study was a double-blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::191dcd131673d406aee7128aaf63ffff
https://pubmed.ncbi.nlm.nih.gov/27221771

Zobrazit plný text záznamu

Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia

Autor: Elizabeth Carreón-Torres, Martha Franco, Victoria López-Olmos, Angélica Arzola-Paniagua, Juan Á. Zamora-Pérez, María Luna-Luna, Oscar Pérez-Méndez, José Manuel Fragoso, José Manuel Rodríguez-Pérez, Carlos A. Aguilar-Salinas, Cristobal Flores-Castillo, Gilberto Vargas-Alarcón

Publikováno v: Fundamentalclinical pharmacology. 29(4)

The anti-atherogenic properties of high-density lipoproteins (HDLs) may be related to their structure and metabolism. The HDL physicochemical characteristics that determine their plasma clearance during treatment with statins and fibrates are not wel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a74c76fb0d3925b981e3b14eba2c07b0
https://pubmed.ncbi.nlm.nih.gov/25982284

Zobrazit plný text záznamu

Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: A randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects

Autor: Maricela Martínez-Delgado, Omar Patiño-Rodríguez, Rosa María Martínez-Medina, Amador Covarrubias-Pinedo, José Luis Herrera-Torres, Abraham Escobedo-Moratilla, América Susana Mares-García, José Pérez-Urizar, Irma Torres-Roque, Angélica Arzola-Paniagua

Publikováno v: Frontiers in Pharmacology, Vol 6 (2015)
Frontiers in Pharmacology

Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0834979ea5d2b3bbee631c6ff0a8ff29
http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00004/full

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report

Autor: Sebastián, Carranza-Lira, Ana Luz Mac Gregor, Gooch, Guillermina, Velasco-Díaz, Jacqueline, Solano, Angélica, Arzola-Paniagua

Publikováno v: International journal of fertility and women's medicine. 51(4)

Recent clinical trials have caused physicians to reconsider the use of hormone therapy (HT). Low-dose therapy has been proposed for those patients who tolerate standard doses poorly.to evaluate low-dose and ultra low-dose estrogen therapy (ET) for va

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b628f3b8742208e43c3292a3976af077
https://pubmed.ncbi.nlm.nih.gov/17184102

Zobrazit plný text záznamu

Fenoverine vs. mefenamic acid in the treatment of primary dysmenorrhea

Autor: J. Lira-Plascencia, A. Arzola-Paniagua, Sebastián Carranza-Lira

Publikováno v: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 93(1)

Mefenamic acid is a nonsteroidal anti-inflammatory drug and a prostaglandin inhibitor useful in the treatment of patients with primary dysmenorrhea and fenoverine is a calcium modulator prescribed as an antispasmodic. The goal of this study was to co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc60cc0091d75af41a7939b29f47c706
https://pubmed.ncbi.nlm.nih.gov/16524578

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání